SAN DIEGO, CA and VANCOUVER, Nov. 30, 2012 /CNW/ - Sophiris Bio, Inc.
(TSX: SHS) today announced the appointment of Noah Knauf as a director
of the Company. Mr. Knauf replaces Jonathan Leff, who has resigned as
a director, as a Warburg Pincus nominee director.
Mr. Knauf focuses on healthcare and life sciences as an investment
professional at Warburg Pincus. He currently serves on the Boards of
Directors of Constitution Medical Investors, Home Dialysis Plus,
International Technidyne Corporation, Keystone Dental, RegionalCare
Hospital Partners and Silk Road Medical. Prior to joining Warburg
Pincus, Mr. Knauf was an Associate at Parthenon Capital, a private
equity firm, and a consultant with Bain & Company, a global consulting
firm. He holds an MBA from Stanford University Graduate School of
Business where he was an Arjay Miller Scholar, and earned a Bachelor of
Science in Business Administration degree (BSBA) from the University of
Sophiris Bio would like to thank Jonathan Leff for his service to the
board and to the Company.
Sophiris Bio Inc. is a urology company developing a late-stage, highly
targeted treatment for the symptoms of benign prostatic hyperplasia
(BPH or enlarged prostate), an unsatisfied market with significant
demand. PRX302, the company's product candidate for the symptoms of
BPH, is designed to be as efficacious as pharmaceuticals, less invasive
than the surgical interventions, and without the sexual side effects
seen with existing treatments. Sophiris is planning to begin a pivotal
trial in the first half of 2013. Sophiris is advised by leading
urologists, backed by experienced investors, and led by a team that has
achieved more than twenty drug approvals. For more information, please
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on Sophiris' current beliefs as
well as assumptions made by and information currently available to
Sophiris and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments,
market acceptance and future commitments. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
Sophiris in its public securities filings; actual events may differ
materially from current expectations. Sophiris disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
SOURCE: Sophiris Bio, Inc.
For further information:
The Trout Group
Jason I. Spark
Canale Communications, Inc.